+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Psychobiotics Market by Strain Type (Bacillus, Bifidobacterium, Lactobacillus), Application (Functional Food & Beverage, Nutraceutical & Dietary Supplement, Pharmaceutical), Product Form, Distribution, End User - Global Forecast 2025-2030- Product Image
Psychobiotics Market by Strain Type (Bacillus, Bifidobacterium, Lactobacillus), Application (Functional Food & Beverage, Nutraceutical & Dietary Supplement, Pharmaceutical), Product Form, Distribution, End User - Global Forecast 2025-2030- Product Image
New

Psychobiotics Market by Strain Type (Bacillus, Bifidobacterium, Lactobacillus), Application (Functional Food & Beverage, Nutraceutical & Dietary Supplement, Pharmaceutical), Product Form, Distribution, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6134248
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Psychobiotics represent a novel class of live microorganisms that, when ingested in adequate amounts, exert mental health benefits through interactions between the gut and the central nervous system. This emerging discipline builds upon decades of microbiome research, refining our understanding of how specific bacterial strains can influence mood, cognition, and stress resilience. Through the secretion of neuroactive compounds, modulation of the hypothalamic-pituitary-adrenal axis, and interaction with enteric nervous system pathways, psychobiotic interventions are poised to transform conventional approaches to anxiety, depression, and other neuropsychiatric disorders.

In recent years, robust preclinical studies have begun to translate into human clinical trials, underscoring the therapeutic potential of targeted bacterial therapies. Moreover, advancements in sequencing technologies, metabolomics, and computational modeling have enabled more precise strain selection and formulation design. As healthcare systems worldwide grapple with rising mental health burdens, the integration of psychobiotics into integrative care pathways offers a promising avenue to alleviate systemic pressures. Consequently, industry, academia, and regulatory bodies are converging to establish rigorous frameworks for safety, efficacy, and quality control. This executive summary consolidates the latest developments, paradigm shifts, and strategic considerations that will define the trajectory of psychobiotics in both research and commercial contexts.

Identifying Key Shifts and Emerging Paradigms That Are Transforming the Psychobiotics Landscape Across Research, Regulation, and Consumer Adoption Trends

Cutting-edge advances in genomic sequencing and bioinformatics have accelerated our understanding of how psychobiotic strains interact with host physiology. Researchers are moving beyond single-strain interventions toward sophisticated bacterial consortia capable of producing neuromodulators such as gamma-aminobutyric acid, serotonin precursors, and short-chain fatty acids. In tandem, digital health platforms are enabling real-time monitoring of gut-brain axis biomarkers, which paves the way for personalized recommendations and adaptive dosing regimens. As a result, the nature of evidence generation has shifted from anecdotal wellness claims to rigorous, reproducible clinical protocols that meet the standards of conventional pharmaceutical trials.

Meanwhile, regulatory frameworks are evolving to accommodate the hybrid status of psychobiotics as both dietary supplements and potential therapeutic agents. Authorities are beginning to define quality benchmarks for strain identification, viability assays, and contaminant testing. These clarifications are supporting a more transparent product development process and reducing barriers to market entry. Simultaneously, consumer demand for holistic mental wellbeing continues to rise, driven by increasing awareness of gut health and the limitations of pharmacological treatments. This confluence of scientific validation, regulatory alignment, and consumer education is catalyzing a transformative phase in the psychobiotics landscape.

Assessing How Recent Tariff Policies in the United States Will Influence Manufacturing, Import Dynamics, and Innovation Trajectories for Psychobiotic Products

The introduction of new tariffs on specialty fermentation equipment, raw materials, and packaging components in the United States has introduced both challenges and strategic opportunities for psychobiotic manufacturers. Import costs for critical bacterial growth media and proprietary encapsulation technologies have increased, prompting many developers to reevaluate their supply chains. In response, some organizations have accelerated the domestic qualification of alternative sourcing partners while others are investing in backward integration to secure raw material control. At the same time, tariff-induced cost pressures have incentivized the establishment of regional production hubs, thereby reducing transit times and exposure to international trade disruptions.

These policy changes are also influencing innovation trajectories. Companies are exploring novel bioreactor designs and continuous processing methods to enhance production efficiencies and offset higher input costs. Additionally, collaborative agreements between domestic research institutions and contract manufacturers have emerged as a mechanism to pool resources and share tariff burdens. Over time, this recalibrated manufacturing landscape is likely to foster a more resilient ecosystem in which regional clusters support localized development, formulation, and distribution of psychobiotic products.

Unveiling Segmentation Insights Across Strain Types, Application Domains, Product Forms, Distribution Channels, and End User Groups in Psychobiotics

Insights into psychobiotic segmentation reveal a nuanced tapestry of strain-based innovation and targeted applications. Within strain typologies, Bacillus species-principally B Coagulans-are prized for their spore-forming robustness, while Bifidobacterium strains such as B Bifidum and B Longum deliver nuanced immune and gut barrier support. Lactobacillus variants, notably L Plantarum and L Rhamnosus, offer distinct psychotropic metabolite profiles that modulate neurotransmitter synthesis. These strain-specific characteristics guide developers toward bespoke formulations designed to address specific mood or stress-related endpoints.

Application domains further diversify the field. Functional food and beverage developers integrate psychobiotic strains into both dairy-based and plant-based formulations, aiming to enhance everyday nutrition with cognitive and emotional support. The nutraceutical and dietary supplement sector explores both multi-strain complexes for broad-spectrum effects and single-strain products for targeted outcomes. Meanwhile, pharmaceutical-grade psychobiotics are navigating stringent regulatory pathways to deliver clinically validated therapies. The offering spectrum spans capsules, liquids, powders, and tablets, each format selected to optimize stability, palatability, and dosing precision. Distribution channels range from pharmacies and specialty retail locations to direct-to-consumer digital storefronts and major e-commerce platforms. End users encompass adults seeking stress relief, geriatric populations managing age-related cognitive decline, and pediatric segments addressing developmental wellness needs.

Mapping Regional Growth Drivers and Market Dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific Psychobiotics Sectors

In the Americas, established wellness markets and progressive regulatory guidance have fostered early adoption of psychobiotic products. North American consumers benefit from widespread access to integrative healthcare providers and digital health monitoring tools, while Latin American regions show promise through traditional knowledge of fermented foods combined with growing mental health awareness. Investment in local clinical studies and pilot production facilities continues to bolster confidence in novel formulations.

Across Europe, Middle East & Africa, the landscape is marked by heterogeneous regulatory environments and diverse cultural influences. Western European nations lead with stringent safety evaluations and reimbursement frameworks, whereas emerging markets in the Middle East and North Africa exhibit heightened consumer interest but varying approval timelines. Meanwhile, sub-Saharan Africa, though nascent in commercial penetration, demonstrates strong potential through indigenous fermentative practices and increasing funding for mental health initiatives.

Asia-Pacific stands out for rapid urbanization, government support for biotechnology sectors, and a deep heritage of probiotic-rich dietary traditions. Consumer wellness trends intersect with national programs targeting mental health, driving both research collaborations and scaled manufacturing investments. From Japan’s advanced clinical infrastructures to India’s burgeoning nutraceutical industry, this region is setting new benchmarks for psychobiotic discovery, production efficiency, and cross-border distribution.

Showcasing Industry Pioneers and Their Strategic Initiatives That Are Driving Innovation, Collaboration, and Competitive Positioning in Psychobiotics

Several pioneering companies are positioning themselves at the forefront of psychobiotics innovation through strategic alliances, acquisitions, and internal R&D investments. Leading food science conglomerates have forged partnerships with academic centers to co-develop proprietary strains, enabling seamless technology transfer from lab to production. Dedicated life sciences firms are expanding their pipelines beyond traditional probiotic formulations, licensing neuroactive bacterial candidates for next-generation therapies. Meanwhile, specialized ingredient providers are collaborating with digital health startups to integrate microbiome data analytics into consumer-facing mobile applications.

Emerging challengers and startups are similarly reshaping the ecosystem. These nimble organizations often focus on high-purity culture processes and rapid clinical validation, creating differentiation through strain exclusivity and targeted health claims. All the while, contract manufacturers and CDMOs are scaling bioprocessing capabilities specifically for psychobiotics, accommodating both spore-based and non-spore formulations. This confluence of strategic joint ventures, vertical integration, and specialized manufacturing alliances is catalyzing competitive positioning and accelerating the pace of product commercialization.

Actionable Recommendations and Strategic Roadmaps for Industry Leaders to Capitalize on Emerging Opportunities and Navigate Challenges in the Psychobiotics Domain

To capitalize on evolving opportunities in the psychobiotics domain, industry leaders should prioritize the design and execution of rigorous clinical studies that validate strain-specific outcomes. Establishing robust partnerships with academic institutions and clinical research organizations will streamline regulatory submissions and bolster consumer trust. Concurrently, diversifying supply chains through regional sourcing agreements and strategic alliances can mitigate the impact of trade policies and logistics disruptions.

At the same time, organizations must invest in digital platforms that integrate consumer feedback, microbiome analytics, and personalized dosing protocols. Engaging directly with healthcare professionals and mental health advocates will amplify educational initiatives and support informed decision-making. Finally, sustainability considerations-from ecofriendly manufacturing to transparent ingredient traceability-will strengthen brand reputation and meet rising consumer expectations around ethical production. By executing a balanced roadmap that addresses scientific rigor, operational resilience, and market-centric innovation, industry players can navigate challenges and secure long-term growth.

Detailing the Rigorous Research Methodology and Analytical Frameworks Underpinning the Psychobiotics Market Study for Enhanced Reliability and Transparency

This research leverages a mixed-methods approach that begins with an exhaustive review of peer-reviewed journals, patent filings, clinical trial registries, and regulatory documentation. Secondary data sources include global health agency reports and academic conference proceedings, ensuring a comprehensive foundation for analysis. Subsequent to secondary research, primary insights were collected through in-depth interviews with key opinion leaders spanning microbiologists, gastroenterologists, neuroscientists, and regulatory experts.

Analytical frameworks such as SWOT assessment, PESTLE analysis, and competitive profiling were applied to distill strategic imperatives from the assembled data. All findings underwent a multi-tiered triangulation process, which included cross-verification between expert feedback and publicly available corporate disclosures. Internal quality checks ensured consistency, accuracy, and neutrality, resulting in a transparent and credible study that guides stakeholders through the complex psychobiotics landscape.

Summarizing Key Findings and Reinforcing the Strategic Imperatives That Define the Future Trajectory of Psychobiotics Research and Industry Development

The evolution of psychobiotics is characterized by an expanding base of scientific validation, progressive regulatory pathways, and growing consumer demand for mental wellbeing solutions. Breakthroughs in strain-specific effects have elevated research standards, while regulatory agencies continue to refine guidelines that balance innovation with safety. Strategic partnerships and targeted investments are accelerating product pipelines, and regional production hubs are emerging as resilient alternatives to global supply chain uncertainties.

Looking ahead, the strategic imperatives for stakeholders include deepening clinical validation, fostering cross-disciplinary collaborations, and leveraging digital health technologies to personalize interventions. Sustainability and ethical sourcing will become differentiators in brand positioning, and proactive engagement with regulatory bodies will smooth market entry and reimbursement processes. By aligning scientific innovation with consumer needs and operational agility, industry participants can chart a clear path toward sustained leadership in the psychobiotics arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Strain Type
    • Bacillus
      • B Coagulans
    • Bifidobacterium
      • B Bifidum
      • B Longum
    • Lactobacillus
      • L Plantarum
      • L Rhamnosus
  • Application
    • Functional Food & Beverage
      • Dairy-Based
      • Non-Dairy
    • Nutraceutical & Dietary Supplement
      • Multi-Strain
      • Single-Strain
    • Pharmaceutical
  • Product Form
    • Capsule
    • Liquid
    • Powder
    • Tablet
  • Distribution
    • Offline
      • Pharmacy
      • Retail Store
      • Specialty Store
    • Online
      • Direct-To-Consumer
      • E-Commerce
  • End User
    • Adult
    • Geriatric
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Danone S.A.
  • Yakult Honsha Co., Ltd.
  • Nestlé S.A.
  • Chr. Hansen Holding A/S
  • Kerry Group plc
  • DuPont de Nemours, Inc.
  • Royal DSM N.V.
  • BioGaia AB
  • Lifeway Foods, Inc.
  • Probi AB

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Personalized psychobiotic formulations targeting individualized mental health profiles and genomic markers
5.2. Integration of psychobiotics into digital health platforms for real-time gut-brain axis monitoring
5.3. Expansion of psychobiotic product lines fortified with novel prebiotics to enhance probiotic efficacy
5.4. Emergence of clinical dermatology applications using psychobiotics to address neuroinflammatory skin disorders
5.5. Regulatory harmonization efforts shaping global psychobiotic ingredient approvals and labeling standards
5.6. Collaboration between pharmaceutical companies and nutraceutical brands to develop psychobiotic prescription protocols
5.7. Advances in fermented functional beverages delivering targeted psychobiotics for mood and cognition support
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Psychobiotics Market, by Strain Type
8.1. Introduction
8.2. Bacillus
8.2.1. B Coagulans
8.3. Bifidobacterium
8.3.1. B Bifidum
8.3.2. B Longum
8.4. Lactobacillus
8.4.1. L Plantarum
8.4.2. L Rhamnosus
9. Psychobiotics Market, by Application
9.1. Introduction
9.2. Functional Food & Beverage
9.2.1. Dairy-Based
9.2.2. Non-Dairy
9.3. Nutraceutical & Dietary Supplement
9.3.1. Multi-Strain
9.3.2. Single-Strain
9.4. Pharmaceutical
10. Psychobiotics Market, by Product Form
10.1. Introduction
10.2. Capsule
10.3. Liquid
10.4. Powder
10.5. Tablet
11. Psychobiotics Market, by Distribution
11.1. Introduction
11.2. Offline
11.2.1. Pharmacy
11.2.2. Retail Store
11.2.3. Specialty Store
11.3. Online
11.3.1. Direct-To-Consumer
11.3.2. E-Commerce
12. Psychobiotics Market, by End User
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Americas Psychobiotics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Psychobiotics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Psychobiotics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Danone S.A.
16.3.2. Yakult Honsha Co., Ltd.
16.3.3. Nestlé S.A.
16.3.4. Chr. Hansen Holding A/S
16.3.5. Kerry Group plc
16.3.6. DuPont de Nemours, Inc.
16.3.7. Royal DSM N.V.
16.3.8. BioGaia AB
16.3.9. Lifeway Foods, Inc.
16.3.10. Probi AB
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PSYCHOBIOTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PSYCHOBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PSYCHOBIOTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PSYCHOBIOTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PSYCHOBIOTICS MARKET: RESEARCHAI
FIGURE 26. PSYCHOBIOTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. PSYCHOBIOTICS MARKET: RESEARCHCONTACTS
FIGURE 28. PSYCHOBIOTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PSYCHOBIOTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PSYCHOBIOTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PSYCHOBIOTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY B COAGULANS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY B COAGULANS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY B BIFIDUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY B BIFIDUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY B LONGUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY B LONGUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY L PLANTARUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY L PLANTARUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY L RHAMNOSUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY L RHAMNOSUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY DAIRY-BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY DAIRY-BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY NON-DAIRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY NON-DAIRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY MULTI-STRAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY MULTI-STRAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY SINGLE-STRAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY SINGLE-STRAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY RETAIL STORE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY RETAIL STORE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY SPECIALTY STORE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY SPECIALTY STORE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY E-COMMERCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL PSYCHOBIOTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES PSYCHOBIOTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 143. CANADA PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 144. CANADA PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 145. CANADA PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 146. CANADA PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 147. CANADA PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 148. CANADA PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 149. CANADA PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 150. CANADA PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 151. CANADA PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 152. CANADA PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 153. CANADA PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 154. CANADA PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 155. CANADA PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 156. CANADA PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 157. CANADA PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 158. CANADA PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 159. CANADA PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 160. CANADA PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 161. CANADA PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 162. CANADA PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 163. CANADA PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 164. CANADA PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 165. CANADA PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. CANADA PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. MEXICO PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 172. MEXICO PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 173. MEXICO PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. MEXICO PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. MEXICO PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 178. MEXICO PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 179. MEXICO PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 180. MEXICO PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 181. MEXICO PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 182. MEXICO PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 183. MEXICO PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 184. MEXICO PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 185. MEXICO PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 186. MEXICO PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 187. MEXICO PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 188. MEXICO PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 189. MEXICO PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. MEXICO PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA PSYCHOBIOTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. GERMANY PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 290. GERMANY PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 291. GERMANY PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 292. GERMANY PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 293. GERMANY PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 294. GERMANY PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 295. GERMANY PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 296. GERMANY PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 297. GERMANY PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 298. GERMANY PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 299. GERMANY PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 300. GERMANY PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 301. GERMANY PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 302. GERMANY PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 303. GERMANY PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 304. GERMANY PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 305. GERMANY PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 306. GERMANY PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 307. GERMANY PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 308. GERMANY PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 309. GERMANY PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 310. GERMANY PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 311. GERMANY PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. GERMANY PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. FRANCE PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 314. FRANCE PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 315. FRANCE PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 316. FRANCE PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 317. FRANCE PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 318. FRANCE PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 319. FRANCE PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 320. FRANCE PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 321. FRANCE PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 322. FRANCE PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 323. FRANCE PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 324. FRANCE PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 325. FRANCE PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 326. FRANCE PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 327. FRANCE PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 328. FRANCE PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 329. FRANCE PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 330. FRANCE PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 331. FRANCE PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 332. FRANCE PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 333. FRANCE PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 334. FRANCE PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 335. FRANCE PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 336. FRANCE PSYCHOBIOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 337. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2018-2024 (USD MILLION)
TABLE 338. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY STRAIN TYPE, 2025-2030 (USD MILLION)
TABLE 339. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2018-2024 (USD MILLION)
TABLE 340. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY BACILLUS, 2025-2030 (USD MILLION)
TABLE 341. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2018-2024 (USD MILLION)
TABLE 342. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY BIFIDOBACTERIUM, 2025-2030 (USD MILLION)
TABLE 343. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2018-2024 (USD MILLION)
TABLE 344. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY LACTOBACILLUS, 2025-2030 (USD MILLION)
TABLE 345. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 346. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 347. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2018-2024 (USD MILLION)
TABLE 348. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY FUNCTIONAL FOOD & BEVERAGE, 2025-2030 (USD MILLION)
TABLE 349. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2018-2024 (USD MILLION)
TABLE 350. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY NUTRACEUTICAL & DIETARY SUPPLEMENT, 2025-2030 (USD MILLION)
TABLE 351. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 352. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 353. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 354. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 355. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 356. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 357. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
TABLE 358. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY ONLINE, 2025-2030 (USD MILLION)
TABLE 359. RUSSIA PSYCHOBIOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Psychobiotics market report include:
  • Danone S.A.
  • Yakult Honsha Co., Ltd.
  • Nestlé S.A.
  • Chr. Hansen Holding A/S
  • Kerry Group plc
  • DuPont de Nemours, Inc.
  • Royal DSM N.V.
  • BioGaia AB
  • Lifeway Foods, Inc.
  • Probi AB

Related Topics

Related Reports

Psychobiotic Supplements Market by Product Type (Capsules, Chewables, Liquid Supplements), Probiotic Strain (Bifidobacterium, Lactobacillus, Streptococcus thermophilus), Source, Distribution Channel, Application, End-User - Global Forecast 2025-2030 - Product Image

Psychobiotic Supplements Market by Product Type (Capsules, Chewables, Liquid Supplements), Probiotic Strain (Bifidobacterium, Lactobacillus, Streptococcus thermophilus), Source, Distribution Channel, Application, End-User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
2025 Psychobiotic Supplements Market Report - Industry Size, Competition, Trends and Growth Opportunities by Region - Forecast by Types and Applications (2024-2032) - Product Image

2025 Psychobiotic Supplements Market Report - Industry Size, Competition, Trends and Growth Opportunities by Region - Forecast by Types and Applications (2024-2032)

  • Report
  • 147 Pages
  • Global
From
Psychobiotics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Psychotropic Agent, By Form, By Application, By Region and Competition - Product Image

Psychobiotics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Psychotropic Agent, By Form, By Application, By Region and Competition

  • Report
  • 110 Pages
  • Global
From
Microbiome Technologies for Nutraceuticals and Personal Care: Technology and Application Analysis - Product Image

Microbiome Technologies for Nutraceuticals and Personal Care: Technology and Application Analysis

  • Report
  • 56 Pages
  • Global
From
Small Animal Microbiomes and Nutrition. Edition No. 1 - Product Image

Small Animal Microbiomes and Nutrition. Edition No. 1

  • Book
  • 384 Pages
Copyright © 2002-2025 Research and Markets. All Rights Reserved.